ID   HPSE_HUMAN              Reviewed;         543 AA.
AC   Q9Y251; A9JIG7; C7F7I3; C7F7I4; E9PCA9; E9PGR1; Q53GE5; Q9UL39;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   07-APR-2021, entry version 178.
DE   RecName: Full=Heparanase;
DE            EC=3.2.1.166;
DE   AltName: Full=Endo-glucoronidase;
DE   AltName: Full=Heparanase-1;
DE            Short=Hpa1;
DE   Contains:
DE     RecName: Full=Heparanase 8 kDa subunit;
DE   Contains:
DE     RecName: Full=Heparanase 50 kDa subunit;
DE   Flags: Precursor;
GN   Name=HPSE; Synonyms=HEP, HPA, HPA1, HPR1, HPSE1, HSE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ARG-307, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10405343; DOI=10.1006/bbrc.1999.0962;
RA   Kussie P.H., Hulmes J.D., Ludwig D.L., Patel S., Navarro E.C., Seddon A.P.,
RA   Giorgio N.A., Bohlen P.;
RT   "Cloning and functional expression of a human heparanase gene.";
RL   Biochem. Biophys. Res. Commun. 261:183-187(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES,
RP   PROTEIN SEQUENCE OF 158-168; 326-337 AND 447-491, AND VARIANT ARG-307.
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=10446189; DOI=10.1074/jbc.274.34.24153;
RA   Toyoshima M., Nakajima M.;
RT   "Human heparanase. Purification, characterization, cloning, and
RT   expression.";
RL   J. Biol. Chem. 274:24153-24160(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), GLYCOSYLATION, PROTEOLYTIC
RP   PROCESSING, AND VARIANT ARG-307.
RX   PubMed=10395325; DOI=10.1038/10518;
RA   Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R.,
RA   Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L.,
RA   Pecker I.;
RT   "Mammalian heparanase: gene cloning, expression and function in tumor
RT   progression and metastasis.";
RL   Nat. Med. 5:793-802(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, PROTEIN
RP   SEQUENCE OF 158-174; 263-272; 326-337; 433-436; 438-443; 466-468 AND
RP   478-483, AND VARIANT ARG-307.
RC   TISSUE=Placenta;
RX   PubMed=10395326; DOI=10.1038/10525;
RA   Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J.,
RA   Parish C.R.;
RT   "Cloning of mammalian heparanase, an important enzyme in tumor invasion and
RT   metastasis.";
RL   Nat. Med. 5:803-809(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES,
RP   TISSUE SPECIFICITY, AND VARIANT ARG-307.
RC   TISSUE=Placenta;
RX   PubMed=10764835; DOI=10.1093/glycob/10.5.467;
RA   Dempsey L.A., Plummer T.B., Coombes S.L., Platt J.L.;
RT   "Heparanase expression in invasive trophoblasts and acute vascular
RT   damage.";
RL   Glycobiology 10:467-475(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RX   PubMed=11547900; DOI=10.1023/a:1011375624902;
RA   Zcharia E., Metzger S., Chajek-Shaul T., Friedmann Y., Pappo O., Aviv A.,
RA   Elkin M., Pecker I., Peretz T., Vlodavsky I.;
RT   "Molecular properties and involvement of heparanase in cancer progression
RT   and mammary gland morphogenesis.";
RL   J. Mammary Gland Biol. Neoplasia 6:311-322(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 36-41 AND
RP   158-163, SUBUNIT, GLYCOSYLATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Placenta;
RX   PubMed=12713442; DOI=10.1042/bj20030318;
RA   McKenzie E., Young K., Hircock M., Bennett J., Bhaman M., Felix R.,
RA   Turner P., Stamps A., McMillan D., Saville G., Ng S., Mason S., Snell D.,
RA   Schofield D., Gong H., Townsend R., Gallagher J., Page M., Parekh R.,
RA   Stubberfield C.;
RT   "Biochemical characterization of the active heterodimer form of human
RT   heparanase (Hpa1) protein expressed in insect cells.";
RL   Biochem. J. 373:423-435(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE SPLICING, AND VARIANT
RP   ARG-307.
RC   TISSUE=Kidney;
RX   PubMed=17208203; DOI=10.1016/j.bbrc.2006.12.189;
RA   Nasser N.J., Avivi A., Shushy M., Vlodavsky I., Nevo E.;
RT   "Cloning, expression, and characterization of an alternatively spliced
RT   variant of human heparanase.";
RL   Biochem. Biophys. Res. Commun. 354:33-38(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RA   Pinhal M.A., Semedo P.;
RT   "Cloned heparanase from MCF-7 cells.";
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), AND VARIANT ARG-307.
RA   Jin S., Yu L., Gong F.;
RT   "Two new transcript variants of Homo sapiens heparanase (HPSE).";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RC   TISSUE=Small intestine;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   MUTAGENESIS OF GLU-225; GLU-343 AND ASP-367.
RX   PubMed=11123890; DOI=10.1021/bi002080p;
RA   Hulett M.D., Hornby J.R., Ohms S.J., Zuegg J., Freeman C., Gready J.E.,
RA   Parish C.R.;
RT   "Identification of active-site residues of the pro-metastatic
RT   endoglycosidase heparanase.";
RL   Biochemistry 39:15659-15667(2000).
RN   [15]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND INTERACTION WITH SDC1.
RX   PubMed=12441129; DOI=10.1006/excr.2002.5651;
RA   Goldshmidt O., Nadav L., Aingorn H., Irit C., Feinstein N., Ilan N.,
RA   Zamir E., Geiger B., Vlodavsky I., Katz B.Z.;
RT   "Human heparanase is localized within lysosomes in a stable form.";
RL   Exp. Cell Res. 281:50-62(2002).
RN   [16]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=12213822; DOI=10.1074/jbc.m206510200;
RA   Okada Y., Yamada S., Toyoshima M., Dong J., Nakajima M., Sugahara K.;
RT   "Structural recognition by recombinant human heparanase that plays critical
RT   roles in tumor metastasis. Hierarchical sulfate groups with different
RT   effects and the essential target disulfated trisaccharide sequence.";
RL   J. Biol. Chem. 277:42488-42495(2002).
RN   [17]
RP   PROTEOLYTIC PROCESSING, ENZYME ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11973358;
RA   Nadav L., Eldor A., Yacoby-Zeevi O., Zamir E., Pecker I., Ilan N.,
RA   Geiger B., Vlodavsky I., Katz B.Z.;
RT   "Activation, processing and trafficking of extracellular heparanase by
RT   primary human fibroblasts.";
RL   J. Cell Sci. 115:2179-2187(2002).
RN   [18]
RP   HETERODIMERIZATION, AND ENZYME ACTIVITY.
RX   PubMed=12927802; DOI=10.1016/s0006-291x(03)01478-5;
RA   Levy-Adam F., Miao H.Q., Heinrikson R.L., Vlodavsky I., Ilan N.;
RT   "Heterodimer formation is essential for heparanase enzymatic activity.";
RL   Biochem. Biophys. Res. Commun. 308:885-891(2003).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF GLU-225.
RX   PubMed=12773484; DOI=10.1096/fj.02-0773com;
RA   Goldshmidt O., Zcharia E., Cohen M., Aingorn H., Cohen I., Nadav L.,
RA   Katz B.Z., Geiger B., Vlodavsky I.;
RT   "Heparanase mediates cell adhesion independent of its enzymatic activity.";
RL   FASEB J. 17:1015-1025(2003).
RN   [20]
RP   GLYCOSYLATION AT ASN-162; ASN-178; ASN-200; ASN-217; ASN-238 AND ASN-459,
RP   AND MUTAGENESIS OF ASN-162; ASN-178; ASN-200; ASN-217; ASN-238 AND ASN-459.
RX   PubMed=14573609; DOI=10.1074/jbc.m300541200;
RA   Simizu S., Ishida K., Wierzba M.K., Osada H.;
RT   "Secretion of heparanase protein is regulated by glycosylation in human
RT   tumor cell lines.";
RL   J. Biol. Chem. 279:2697-2703(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=15044433; DOI=10.1074/jbc.m400554200;
RA   Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Heparanase induces endothelial cell migration via protein kinase B/Akt
RT   activation.";
RL   J. Biol. Chem. 279:23536-23541(2004).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15292202; DOI=10.1074/jbc.m402131200;
RA   Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E.,
RA   Levy-Adam F., Bashenko Y., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Heparanase uptake is mediated by cell membrane heparan sulfate
RT   proteoglycans.";
RL   J. Biol. Chem. 279:44084-44092(2004).
RN   [23]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=15126626; DOI=10.1242/jcs.01068;
RA   Zetser A., Levy-Adam F., Kaplan V., Gingis-Velitski S., Bashenko Y.,
RA   Schubert S., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Processing and activation of latent heparanase occurs in lysosomes.";
RL   J. Cell Sci. 117:2249-2258(2004).
RN   [24]
RP   BIOPHYSICOCHEMICAL PROPERTIES, PROTEOLYTIC PROCESSING, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15848168; DOI=10.1016/j.febslet.2005.03.030;
RA   Cohen E., Atzmon R., Vlodavsky I., Ilan N.;
RT   "Heparanase processing by lysosomal/endosomal protein preparation.";
RL   FEBS Lett. 579:2334-2338(2005).
RN   [25]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF TYR-156.
RX   PubMed=15659389; DOI=10.1074/jbc.m413370200;
RA   Abboud-Jarrous G., Rangini-Guetta Z., Aingorn H., Atzmon R., Elgavish S.,
RA   Peretz T., Vlodavsky I.;
RT   "Site-directed mutagenesis, proteolytic cleavage, and activation of human
RT   proheparanase.";
RL   J. Biol. Chem. 280:13568-13575(2005).
RN   [26]
RP   HEPARAN SULFATE-BINDING DOMAINS, AND MUTAGENESIS OF LYS-158 AND LYS-161.
RX   PubMed=15760902; DOI=10.1074/jbc.m414546200;
RA   Levy-Adam F., Abboud-Jarrous G., Guerrini M., Beccati D., Vlodavsky I.,
RA   Ilan N.;
RT   "Identification and characterization of heparin/heparan sulfate binding
RT   domains of the endoglycosidase heparanase.";
RL   J. Biol. Chem. 280:20457-20466(2005).
RN   [27]
RP   FUNCTION.
RX   PubMed=16452201; DOI=10.1158/0008-5472.can-05-1811;
RA   Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N.;
RT   "Heparanase induces vascular endothelial growth factor expression:
RT   correlation with p38 phosphorylation levels and Src activation.";
RL   Cancer Res. 66:1455-1463(2006).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-217.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.m500324-mcp200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [29]
RP   TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=18557927; DOI=10.1111/j.1600-0625.2008.00739.x;
RA   Malgouries S., Donovan M., Thibaut S., Bernard B.A.;
RT   "Heparanase 1: a key participant of inner root sheath differentiation
RT   program and hair follicle homeostasis.";
RL   Exp. Dermatol. 17:1017-1023(2008).
RN   [30]
RP   FUNCTION.
RX   PubMed=18798279; DOI=10.1002/ijc.23898;
RA   Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I.,
RA   Doweck I.;
RT   "Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.";
RL   Int. J. Cancer 123:2566-2573(2008).
RN   [31]
RP   FUNCTION OF THE C-TERMINAL DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   VAL-414; LYS-417; PRO-525; PHE-527; SER-528; TYR-529; PHE-531; VAL-533;
RP   ILE-534; ARG-535; ASN-536; ALA-537; LYS-538; VAL-539; ALA-540; ALA-541 AND
RP   CYS-542.
RX   PubMed=19244131; DOI=10.1158/0008-5472.can-08-1837;
RA   Fux L., Feibish N., Cohen-Kaplan V., Gingis-Velitski S., Feld S.,
RA   Geffen C., Vlodavsky I., Ilan N.;
RT   "Structure-function approach identifies a COOH-terminal domain that
RT   mediates heparanase signaling.";
RL   Cancer Res. 69:1758-1767(2009).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-217 AND ASN-238.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [33]
RP   FUNCTION.
RX   PubMed=20097882; DOI=10.1182/blood-2009-07-234757;
RA   Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K.,
RA   Rapraeger A.C., Sanderson R.D.;
RT   "Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes
RT   endothelial invasion and angiogenesis.";
RL   Blood 115:2449-2457(2010).
RN   [34]
RP   INTERACTION WITH TF, AND ENZYME ACTIVITY.
RX   PubMed=20634491; DOI=10.3324/haematol.2010.023713;
RA   Nadir Y., Brenner B., Fux L., Shafat I., Attias J., Vlodavsky I.;
RT   "Heparanase enhances the generation of activated factor X in the presence
RT   of tissue factor and activated factor VII.";
RL   Haematologica 95:1927-1934(2010).
RN   [35]
RP   INTERACTION WITH HRG, ENZYME ACTIVITY, AND FUNCTION.
RX   PubMed=20561914; DOI=10.1016/j.biocel.2010.05.008;
RA   Poon I.K., Yee D.Y., Jones A.L., Wood R.J., Davis D.S., Freeman C.,
RA   Parish C.R., Hulett M.D.;
RT   "Histidine-rich glycoprotein binds heparanase and regulates its enzymatic
RT   activity and cell surface interactions.";
RL   Int. J. Biochem. Cell Biol. 42:1507-1516(2010).
RN   [36]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=20181948; DOI=10.1074/jbc.m110.104166;
RA   Peterson S.B., Liu J.;
RT   "Unraveling the specificity of heparanase utilizing synthetic substrates.";
RL   J. Biol. Chem. 285:14504-14513(2010).
RN   [37]
RP   INTERACTION WITH HPSE2.
RX   PubMed=20576607; DOI=10.1074/jbc.m110.116384;
RA   Levy-Adam F., Feld S., Cohen-Kaplan V., Shteingauz A., Gross M., Arvatz G.,
RA   Naroditsky I., Ilan N., Doweck I., Vlodavsky I.;
RT   "Heparanase 2 interacts with heparan sulfate with high affinity and
RT   inhibits heparanase activity.";
RL   J. Biol. Chem. 285:28010-28019(2010).
RN   [38]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=20309870; DOI=10.1002/jor.21138;
RA   Smith P.N., Freeman C., Yu D., Chen M., Gatenby P.A., Parish C.R., Li R.W.;
RT   "Heparanase in primary human osteoblasts.";
RL   J. Orthop. Res. 28:1315-1322(2010).
RN   [39]
RP   FUNCTION.
RX   PubMed=21131364; DOI=10.1074/jbc.m110.183277;
RA   Ramani V.C., Yang Y., Ren Y., Nan L., Sanderson R.D.;
RT   "Heparanase plays a dual role in driving hepatocyte growth factor (HGF)
RT   signaling by enhancing HGF expression and activity.";
RL   J. Biol. Chem. 286:6490-6499(2011).
RN   [40] {ECO:0007744|PDB:5E8M, ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98, ECO:0007744|PDB:5E9B, ECO:0007744|PDB:5E9C}
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS) OF 158-543 AND 36-109 IN COMPLEX
RP   WITH HEPARIN, GLYCOSYLATION AT ASN-162; ASN-200; ASN-217; ASN-238 AND
RP   ASN-459, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=26575439; DOI=10.1038/nsmb.3136;
RA   Wu L., Viola C.M., Brzozowski A.M., Davies G.J.;
RT   "Structural characterization of human heparanase reveals insights into
RT   substrate recognition.";
RL   Nat. Struct. Mol. Biol. 22:1016-1022(2015).
RN   [41]
RP   ERRATUM OF PUBMED:26575439.
RX   PubMed=26733221; DOI=10.1038/nsmb0116-91;
RA   Wu L., Viola C.M., Brzozowski A.M., Davies G.J.;
RT   "Corrigendum: Structural characterization of human heparanase reveals
RT   insights into substrate recognition.";
RL   Nat. Struct. Mol. Biol. 23:91-91(2016).
RN   [42] {ECO:0007744|PDB:5L9Y, ECO:0007744|PDB:5L9Z, ECO:0007744|PDB:5LA4, ECO:0007744|PDB:5LA7}
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 36-543 OF PRECURSOR, AND X-RAY
RP   CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 158-543 AND 36-109.
RX   PubMed=28581485; DOI=10.1038/nchembio.2395;
RA   Wu L., Jiang J., Jin Y., Kallemeijn W.W., Kuo C.L., Artola M., Dai W.,
RA   van Elk C., van Eijk M., van der Marel G.A., Codee J.D.C., Florea B.I.,
RA   Aerts J.M.F.G., Overkleeft H.S., Davies G.J.;
RT   "Activity-based probes for functional interrogation of retaining beta-
RT   glucuronidases.";
RL   Nat. Chem. Biol. 13:867-873(2017).
RN   [43]
RP   VARIANT SER-260.
RX   PubMed=15334672; DOI=10.3748/wjg.v10.i19.2795;
RA   Chen X.P., Liu Y.B., Rui J., Peng S.Y., Peng C.H., Zhou Z.Y., Shi L.H.,
RA   Shen H.W., Xu B.;
RT   "Heparanase mRNA expression and point mutation in hepatocellular
RT   carcinoma.";
RL   World J. Gastroenterol. 10:2795-2799(2004).
CC   -!- FUNCTION: Endoglycosidase that cleaves heparan sulfate proteoglycans
CC       (HSPGs) into heparan sulfate side chains and core proteoglycans.
CC       Participates in extracellular matrix (ECM) degradation and remodeling.
CC       Selectively cleaves the linkage between a glucuronic acid unit and an
CC       N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo
CC       group. Can also cleave the linkage between a glucuronic acid unit and
CC       an N-sulfo glucosamine unit carrying a 2-O-sulfo group, but not
CC       linkages between a glucuronic acid unit and a 2-O-sulfated iduronic
CC       acid moiety. It is essentially inactive at neutral pH but becomes
CC       active under acidic conditions such as during tumor invasion and in
CC       inflammatory processes. Facilitates cell migration associated with
CC       metastasis, wound healing and inflammation. Enhances shedding of
CC       syndecans, and increases endothelial invasion and angiogenesis in
CC       myelomas. Acts as procoagulant by increasing the generation of
CC       activation factor X in the presence of tissue factor and activation
CC       factor VII. Increases cell adhesion to the extracellular matrix (ECM),
CC       independent of its enzymatic activity. Induces AKT1/PKB phosphorylation
CC       via lipid rafts increasing cell mobility and invasion. Heparin
CC       increases this AKT1/PKB activation. Regulates osteogenesis. Enhances
CC       angiogenesis through up-regulation of SRC-mediated activation of VEGF.
CC       Implicated in hair follicle inner root sheath differentiation and hair
CC       homeostasis. {ECO:0000269|PubMed:12213822, ECO:0000269|PubMed:12773484,
CC       ECO:0000269|PubMed:15044433, ECO:0000269|PubMed:16452201,
CC       ECO:0000269|PubMed:18557927, ECO:0000269|PubMed:18798279,
CC       ECO:0000269|PubMed:19244131, ECO:0000269|PubMed:20097882,
CC       ECO:0000269|PubMed:20181948, ECO:0000269|PubMed:20309870,
CC       ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:21131364}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Endohydrolysis of (1->4)-beta-D-glycosidic bonds of heparan
CC         sulfate chains in heparan sulfate proteoglycan.; EC=3.2.1.166;
CC         Evidence={ECO:0000269|PubMed:11973358, ECO:0000269|PubMed:12213822,
CC         ECO:0000269|PubMed:12927802, ECO:0000269|PubMed:20181948,
CC         ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:20634491};
CC   -!- ACTIVITY REGULATION: Inhibited by EDTA, laminarin sulfate and, to a
CC       lower extent, by heparin and sulfamin and activated by calcium and
CC       magnesium. {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.7 uM for M09 S05a, a heparin sulfate analog with a
CC         nonasaccharide with N-sulfation and a single GlcNS(6S) toward the
CC         reducing end {ECO:0000269|PubMed:28581485};
CC         Note=Kcat is 0.53 sec(-1) for M09 S05a.
CC         {ECO:0000269|PubMed:28581485};
CC       pH dependence:
CC         Optimum pH is 4-6. {ECO:0000269|PubMed:10446189,
CC         ECO:0000269|PubMed:10764835, ECO:0000269|PubMed:12713442,
CC         ECO:0000269|PubMed:15848168};
CC   -!- SUBUNIT: Heterodimer; heterodimer formation between the 8 kDa and the
CC       50 kDa subunits is required for enzyme activity. Interacts with TF; the
CC       interaction, inhibited by heparin, enhances the generation of activated
CC       factor X and activates coagulation. Interacts with HRG; the interaction
CC       is enhanced at acidic pH, partially inhibits binding of HPSE to cell
CC       surface receptors and modulates its enzymatic activity. Interacts with
CC       SDC1; the interaction enhances the shedding of SDC1. Interacts with
CC       HPSE2. {ECO:0000269|PubMed:12441129, ECO:0000269|PubMed:12713442,
CC       ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:20576607,
CC       ECO:0000269|PubMed:20634491}.
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Peripheral membrane protein.
CC       Secreted. Nucleus. Note=Proheparanase is secreted via vesicles of the
CC       Golgi. Interacts with cell membrane heparan sulfate proteoglycans
CC       (HSPGs). Endocytosed and accumulates in endosomes. Transferred to
CC       lysosomes where it is proteolytically cleaved to produce the active
CC       enzyme. Under certain stimuli, transferred to the cell surface.
CC       Associates with lipid rafts. Colocalizes with SDC1 in
CC       endosomal/lysosomal vesicles. Accumulates in perinuclear lysosomal
CC       vesicles. Heparin retains proheparanase in the extracellular medium (By
CC       similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9Y251-1; Sequence=Displayed;
CC       Name=2; Synonyms=55 kDa, splice 5;
CC         IsoId=Q9Y251-2; Sequence=VSP_044537;
CC       Name=3; Synonyms=ex9-10del;
CC         IsoId=Q9Y251-3; Sequence=VSP_044664;
CC       Name=4; Synonyms=ex10del;
CC         IsoId=Q9Y251-4; Sequence=VSP_053730, VSP_053731;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta and spleen and weakly
CC       expressed in lymph node, thymus, peripheral blood leukocytes, bone
CC       marrow, endothelial cells, fetal liver and tumor tissues. Also
CC       expressed in hair follicles, specifically in both Henle's and Huxley's
CC       layers of inner the root sheath (IRS) at anagen phase.
CC       {ECO:0000269|PubMed:10395326, ECO:0000269|PubMed:10405343,
CC       ECO:0000269|PubMed:10764835, ECO:0000269|PubMed:18557927,
CC       ECO:0000269|PubMed:20309870}.
CC   -!- PTM: Proteolytically processed. The cleavage of the 65 kDa form leads
CC       to the generation of a linker peptide, and 8 kDa and 50 kDa products.
CC       The active form, the 8/50 kDa heterodimer, is resistant to degradation.
CC       Complete removal of the linker peptide appears to be a prerequisite to
CC       the complete activation of the enzyme. {ECO:0000269|PubMed:10395325,
CC       ECO:0000269|PubMed:11973358, ECO:0000269|PubMed:12441129,
CC       ECO:0000269|PubMed:15126626, ECO:0000269|PubMed:15659389,
CC       ECO:0000269|PubMed:15848168}.
CC   -!- PTM: N-glycosylated. Glycosylation of the 50 kDa subunit appears to be
CC       essential for its solubility. {ECO:0000269|PubMed:10395325,
CC       ECO:0000269|PubMed:12713442, ECO:0000269|PubMed:14573609,
CC       ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:19159218}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Escapes proteolytic cleavage, devoid of HS
CC       degradation activity. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 79 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF152376; AAD45669.1; -; mRNA.
DR   EMBL; AF155510; AAD54941.1; -; mRNA.
DR   EMBL; AF144325; AAD41342.1; -; mRNA.
DR   EMBL; AF165154; AAD45379.1; -; mRNA.
DR   EMBL; AF084467; AAD54516.1; -; mRNA.
DR   EMBL; AM419200; CAL91960.1; -; mRNA.
DR   EMBL; AY948074; AAX47106.1; -; mRNA.
DR   EMBL; GQ337901; ACT98237.1; -; mRNA.
DR   EMBL; GQ337902; ACT98238.1; -; mRNA.
DR   EMBL; AK222986; BAD96706.1; -; mRNA.
DR   EMBL; AC114781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC051321; AAH51321.1; -; mRNA.
DR   CCDS; CCDS3602.1; -. [Q9Y251-1]
DR   CCDS; CCDS54774.1; -. [Q9Y251-3]
DR   CCDS; CCDS56337.1; -. [Q9Y251-2]
DR   RefSeq; NP_001092010.1; NM_001098540.2. [Q9Y251-1]
DR   RefSeq; NP_001159970.1; NM_001166498.2. [Q9Y251-3]
DR   RefSeq; NP_001186759.1; NM_001199830.1. [Q9Y251-2]
DR   RefSeq; NP_006656.2; NM_006665.5. [Q9Y251-1]
DR   PDB; 5E8M; X-ray; 1.75 A; A=158-543, B=36-109.
DR   PDB; 5E97; X-ray; 1.63 A; A=158-543, B=36-109.
DR   PDB; 5E98; X-ray; 1.63 A; A=158-543, B=36-109.
DR   PDB; 5E9B; X-ray; 1.88 A; A=158-543, B=36-109.
DR   PDB; 5E9C; X-ray; 1.73 A; A=158-543, B=36-109.
DR   PDB; 5L9Y; X-ray; 1.88 A; A=158-543, B=36-109.
DR   PDB; 5L9Z; X-ray; 1.57 A; A=158-543, B=36-109.
DR   PDB; 5LA4; X-ray; 1.90 A; A=36-543.
DR   PDB; 5LA7; X-ray; 1.94 A; A=36-543.
DR   PDB; 6ZDM; X-ray; 1.71 A; AAA=158-543, BBB=36-109.
DR   PDBsum; 5E8M; -.
DR   PDBsum; 5E97; -.
DR   PDBsum; 5E98; -.
DR   PDBsum; 5E9B; -.
DR   PDBsum; 5E9C; -.
DR   PDBsum; 5L9Y; -.
DR   PDBsum; 5L9Z; -.
DR   PDBsum; 5LA4; -.
DR   PDBsum; 5LA7; -.
DR   PDBsum; 6ZDM; -.
DR   SMR; Q9Y251; -.
DR   BioGRID; 116066; 32.
DR   ComplexPortal; CPX-362; Heparanase complex.
DR   IntAct; Q9Y251; 27.
DR   STRING; 9606.ENSP00000384262; -.
DR   BindingDB; Q9Y251; -.
DR   ChEMBL; CHEMBL3921; -.
DR   DrugBank; DB06779; Dalteparin.
DR   DrugBank; DB01109; Heparin.
DR   DrugCentral; Q9Y251; -.
DR   GuidetoPHARMACOLOGY; 2996; -.
DR   CAZy; GH79; Glycoside Hydrolase Family 79.
DR   GlyGen; Q9Y251; 7 sites.
DR   iPTMnet; Q9Y251; -.
DR   PhosphoSitePlus; Q9Y251; -.
DR   BioMuta; HPSE; -.
DR   DMDM; 296434532; -.
DR   EPD; Q9Y251; -.
DR   jPOST; Q9Y251; -.
DR   MassIVE; Q9Y251; -.
DR   PaxDb; Q9Y251; -.
DR   PeptideAtlas; Q9Y251; -.
DR   PRIDE; Q9Y251; -.
DR   ProteomicsDB; 19409; -.
DR   ProteomicsDB; 20372; -.
DR   ProteomicsDB; 85653; -. [Q9Y251-1]
DR   TopDownProteomics; Q9Y251-1; -. [Q9Y251-1]
DR   ABCD; Q9Y251; 8 sequenced antibodies.
DR   Antibodypedia; 4072; 548 antibodies.
DR   DNASU; 10855; -.
DR   Ensembl; ENST00000311412; ENSP00000308107; ENSG00000173083. [Q9Y251-1]
DR   Ensembl; ENST00000405413; ENSP00000384262; ENSG00000173083. [Q9Y251-1]
DR   Ensembl; ENST00000509906; ENSP00000421038; ENSG00000173083. [Q9Y251-4]
DR   Ensembl; ENST00000512196; ENSP00000423265; ENSG00000173083. [Q9Y251-3]
DR   Ensembl; ENST00000513463; ENSP00000421365; ENSG00000173083. [Q9Y251-2]
DR   GeneID; 10855; -.
DR   KEGG; hsa:10855; -.
DR   UCSC; uc003hoi.4; human. [Q9Y251-1]
DR   CTD; 10855; -.
DR   DisGeNET; 10855; -.
DR   GeneCards; HPSE; -.
DR   HGNC; HGNC:5164; HPSE.
DR   HPA; ENSG00000173083; Low tissue specificity.
DR   MIM; 604724; gene.
DR   neXtProt; NX_Q9Y251; -.
DR   OpenTargets; ENSG00000173083; -.
DR   PharmGKB; PA29435; -.
DR   VEuPathDB; HostDB:ENSG00000173083.14; -.
DR   eggNOG; ENOG502QQST; Eukaryota.
DR   GeneTree; ENSGT00390000004874; -.
DR   HOGENOM; CLU_021823_0_1_1; -.
DR   InParanoid; Q9Y251; -.
DR   OMA; YLHCTNS; -.
DR   OrthoDB; 1132327at2759; -.
DR   PhylomeDB; Q9Y251; -.
DR   TreeFam; TF328999; -.
DR   BioCyc; MetaCyc:ENSG00000173083-MONOMER; -.
DR   BRENDA; 3.2.1.166; 2681.
DR   PathwayCommons; Q9Y251; -.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; Q9Y251; -.
DR   BioGRID-ORCS; 10855; 7 hits in 992 CRISPR screens.
DR   ChiTaRS; HPSE; human.
DR   GeneWiki; Heparanase; -.
DR   GenomeRNAi; 10855; -.
DR   Pharos; Q9Y251; Tchem.
DR   PRO; PR:Q9Y251; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9Y251; protein.
DR   Bgee; ENSG00000173083; Expressed in monocyte and 150 other tissues.
DR   ExpressionAtlas; Q9Y251; baseline and differential.
DR   Genevisible; Q9Y251; HS.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904974; C:heparanase complex; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:0004566; F:beta-glucuronidase activity; TAS:ProtInc.
DR   GO; GO:0030305; F:heparanase activity; IDA:UniProtKB.
DR   GO; GO:0045545; F:syndecan binding; IDA:UniProtKB.
DR   GO; GO:0060055; P:angiogenesis involved in wound healing; IBA:GO_Central.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030200; P:heparan sulfate proteoglycan catabolic process; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:UniProtKB.
DR   GO; GO:0051798; P:positive regulation of hair follicle development; IEA:Ensembl.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:UniProtKB.
DR   GO; GO:0006029; P:proteoglycan metabolic process; TAS:ProtInc.
DR   GO; GO:0051797; P:regulation of hair follicle development; IDA:UniProtKB.
DR   GO; GO:0061042; P:vascular wound healing; IEA:Ensembl.
DR   InterPro; IPR005199; Glyco_hydro_79.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Pfam; PF03662; Glyco_hydro_79n; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Hydrolase;
KW   Lysosome; Magnesium; Membrane; Nucleus; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL          1..35
FT                   /evidence="ECO:0000269|PubMed:12713442"
FT   CHAIN           36..109
FT                   /note="Heparanase 8 kDa subunit"
FT                   /id="PRO_0000042260"
FT   PROPEP          110..157
FT                   /note="Linker peptide"
FT                   /evidence="ECO:0000269|PubMed:10395326,
FT                   ECO:0000269|PubMed:10446189, ECO:0000269|PubMed:12713442"
FT                   /id="PRO_0000042261"
FT   CHAIN           158..543
FT                   /note="Heparanase 50 kDa subunit"
FT                   /id="PRO_0000042262"
FT   REGION          62..64
FT                   /note="Heparan sulfate-binding"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B, ECO:0007744|PDB:5E9C"
FT   REGION          158..162
FT                   /note="Heparan sulfate-binding"
FT                   /evidence="ECO:0000269|PubMed:15760902"
FT   REGION          270..280
FT                   /note="Heparan sulfate-binding"
FT                   /evidence="ECO:0000269|PubMed:15760902,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E9C"
FT   REGION          288..417
FT                   /note="Required for heterodimerization with the heparanase
FT                   8 kDa subunit"
FT                   /evidence="ECO:0000269|PubMed:12927802"
FT   REGION          348..350
FT                   /note="Heparan sulfate-binding"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B"
FT   REGION          389..391
FT                   /note="Heparan sulfate-binding"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B"
FT   REGION          527..543
FT                   /note="Required for transferring proheparanase to the Golgi
FT                   apparatus, secretion and subsequent enzyme activity and for
FT                   enhancement of PKB/AKT1 phosphorylation"
FT   ACT_SITE        225
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000305|PubMed:28581485,
FT                   ECO:0007744|PDB:5E9B"
FT   ACT_SITE        343
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000305|PubMed:28581485,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B"
FT   BINDING         97
FT                   /note="Heparan sulfate; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B"
FT   BINDING         296
FT                   /note="Heparan sulfate"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E9C"
FT   BINDING         303
FT                   /note="Heparan sulfate"
FT                   /evidence="ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E9C"
FT   CARBOHYD        162
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E8M,
FT                   ECO:0007744|PDB:5E97"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   CARBOHYD        200
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E8M,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B, ECO:0007744|PDB:5E9C"
FT   CARBOHYD        217
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609,
FT                   ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E8M"
FT   CARBOHYD        238
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:28581485,
FT                   ECO:0007744|PDB:5E8M, ECO:0007744|PDB:5E97,
FT                   ECO:0007744|PDB:5E98, ECO:0007744|PDB:5E9B,
FT                   ECO:0007744|PDB:5E9C"
FT   CARBOHYD        459
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14573609,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E8M,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B, ECO:0007744|PDB:5E9C"
FT   DISULFID        127..179
FT                   /evidence="ECO:0000269|PubMed:15334672,
FT                   ECO:0007744|PDB:5LA4, ECO:0007744|PDB:5LA7"
FT   DISULFID        437..542
FT                   /evidence="ECO:0000269|PubMed:15334672,
FT                   ECO:0000269|PubMed:28581485, ECO:0007744|PDB:5E8M,
FT                   ECO:0007744|PDB:5E97, ECO:0007744|PDB:5E98,
FT                   ECO:0007744|PDB:5E9B, ECO:0007744|PDB:5E9C,
FT                   ECO:0007744|PDB:5L9Y, ECO:0007744|PDB:5L9Z,
FT                   ECO:0007744|PDB:5LA4, ECO:0007744|PDB:5LA7"
FT   VAR_SEQ         167..225
FT                   /note="RSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNI
FT                   SWELGNE -> K (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17208203"
FT                   /id="VSP_044537"
FT   VAR_SEQ         329..402
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.10"
FT                   /id="VSP_044664"
FT   VAR_SEQ         365..380
FT                   /note="WLDKLGLSARMGIEVV -> IIGYLFCSRNWWAPRC (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.10"
FT                   /id="VSP_053730"
FT   VAR_SEQ         381..543
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.10"
FT                   /id="VSP_053731"
FT   VARIANT         260
FT                   /note="N -> S (in some hepatocellular carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:15334672"
FT                   /id="VAR_023600"
FT   VARIANT         307
FT                   /note="K -> R (in dbSNP:rs11099592)"
FT                   /evidence="ECO:0000269|PubMed:10395325,
FT                   ECO:0000269|PubMed:10395326, ECO:0000269|PubMed:10405343,
FT                   ECO:0000269|PubMed:10446189, ECO:0000269|PubMed:10764835,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17208203,
FT                   ECO:0000269|Ref.10, ECO:0000269|Ref.11, ECO:0000269|Ref.9"
FT                   /id="VAR_068907"
FT   MUTAGEN         156
FT                   /note="Y->A,E: Alteration of the correct processing of
FT                   heparanase which results in the cleavage at an upstream
FT                   site in the linker peptide and no activation of
FT                   proheparanase."
FT                   /evidence="ECO:0000269|PubMed:15659389"
FT   MUTAGEN         156
FT                   /note="Y->V: Normal processing."
FT                   /evidence="ECO:0000269|PubMed:15659389"
FT   MUTAGEN         158
FT                   /note="K->A: No association with GS-modified heparin; when
FT                   associated with K-158."
FT                   /evidence="ECO:0000269|PubMed:15760902"
FT   MUTAGEN         161
FT                   /note="K->A: Two-fold increase in the level of secretion
FT                   upon addition of GS-modified heparin. No association with
FT                   GS-modified heparin; when associated with K-161."
FT                   /evidence="ECO:0000269|PubMed:15760902"
FT   MUTAGEN         162
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction and important decrease of secretion. Larger
FT                   size reduction; when associated with Q-178; Q-200; Q-217;
FT                   Q-238 and Q-459."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         178
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction and important decrease of secretion. Larger
FT                   size reduction; when associated with Q-162; Q-200; Q-217;
FT                   Q-238 and Q-459."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         200
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction and partial decrease in secretion. Larger
FT                   size reduction; when associated with Q-162; Q-178; Q-217;
FT                   Q-238 and Q-459."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         217
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction and partial decrease in secretion. Larger
FT                   size reduction; when associated with Q-162; Q-178; Q-200;
FT                   Q-238 and Q-459."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         225
FT                   /note="E->A: Loss of heparanase activity. No effect on
FT                   HPSE-mediated cell adhesion."
FT                   /evidence="ECO:0000269|PubMed:11123890,
FT                   ECO:0000269|PubMed:12773484"
FT   MUTAGEN         238
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction. Larger size reduction and important
FT                   decrease of secretion; when associated with Q-162; Q-178;
FT                   Q-200; Q-217 and Q-459."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         343
FT                   /note="E->A: Loss of heparanase activity."
FT                   /evidence="ECO:0000269|PubMed:11123890"
FT   MUTAGEN         367
FT                   /note="D->A: Strong decrease in heparanase activity."
FT                   /evidence="ECO:0000269|PubMed:11123890"
FT   MUTAGEN         378
FT                   /note="E->A: No reduction in heparanase activity."
FT   MUTAGEN         396
FT                   /note="E->A: No reduction in heparanase activity."
FT   MUTAGEN         414
FT                   /note="V->K: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         417
FT                   /note="K->E: No effect on processing nor secretion. No
FT                   enzyme activity detected."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         459
FT                   /note="N->Q: Faster electrophoretic migration typical of a
FT                   size reduction. Larger size reduction and important
FT                   decrease of secretion; when associated with Q-162; Q-178;
FT                   Q-200; Q-217 and Q-238."
FT                   /evidence="ECO:0000269|PubMed:14573609"
FT   MUTAGEN         525
FT                   /note="P->G: No effect on processing nor secretion. No
FT                   enzyme activity detected."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         527
FT                   /note="F->R: No effect on processing nor secretion. No
FT                   enzyme activity detected."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         528
FT                   /note="S->K: No effect on processing nor secretion. No
FT                   enzyme activity detected."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         529
FT                   /note="Y->A: No effect on processing nor secretion. No
FT                   enzyme activity detected."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         531
FT                   /note="F->R: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         533
FT                   /note="V->R: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         534
FT                   /note="I->D: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         535
FT                   /note="R->A: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         536
FT                   /note="N->A: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         537
FT                   /note="A->K: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         538
FT                   /note="K->A: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         539
FT                   /note="V->A: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         540
FT                   /note="A->K: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         541
FT                   /note="A->K: No effect on processing, secretion nor enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   MUTAGEN         542
FT                   /note="C->A: Abolishes processing, secretion and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19244131"
FT   CONFLICT        13
FT                   /note="L -> LL (in Ref. 5; AAD54516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        36
FT                   /note="Q -> QQ (in Ref. 5; AAD54516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        291
FT                   /note="D -> G (in Ref. 11; BAD96706)"
FT                   /evidence="ECO:0000305"
FT   STRAND          38..44
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          49..51
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          57..61
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           63..67
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           71..76
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           78..86
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          89..94
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           97..101
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          102..104
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           112..121
FT                   /evidence="ECO:0007744|PDB:5LA4"
FT   HELIX           126..129
FT                   /evidence="ECO:0007744|PDB:5LA4"
FT   HELIX           134..157
FT                   /evidence="ECO:0007744|PDB:5LA4"
FT   STRAND          163..165
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           167..179
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          182..188
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           202..213
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          219..222
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           226..228
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           229..233
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           239..254
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          256..258
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          263..268
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           273..286
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           287..289
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          291..301
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   TURN            302..304
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           307..310
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           313..316
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           318..331
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          338..348
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   TURN            353..357
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           359..361
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           362..375
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          380..383
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          385..389
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           402..413
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          414..418
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          420..423
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          429..438
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          450..456
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          458..460
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          462..465
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          475..482
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          484..486
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           487..489
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          493..495
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          514..516
FT                   /evidence="ECO:0007744|PDB:5LA7"
FT   STRAND          522..524
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   STRAND          528..534
FT                   /evidence="ECO:0007744|PDB:5L9Z"
FT   HELIX           540..542
FT                   /evidence="ECO:0007744|PDB:5L9Z"
SQ   SEQUENCE   543 AA;  61149 MW;  A990F5AFD639CA1A CRC64;
     MLLRSKPALP PPLMLLLLGP LGPLSPGALP RPAQAQDVVD LDFFTQEPLH LVSPSFLSVT
     IDANLATDPR FLILLGSPKL RTLARGLSPA YLRFGGTKTD FLIFDPKKES TFEERSYWQS
     QVNQDICKYG SIPPDVEEKL RLEWPYQEQL LLREHYQKKF KNSTYSRSSV DVLYTFANCS
     GLDLIFGLNA LLRTADLQWN SSNAQLLLDY CSSKGYNISW ELGNEPNSFL KKADIFINGS
     QLGEDFIQLH KLLRKSTFKN AKLYGPDVGQ PRRKTAKMLK SFLKAGGEVI DSVTWHHYYL
     NGRTATKEDF LNPDVLDIFI SSVQKVFQVV ESTRPGKKVW LGETSSAYGG GAPLLSDTFA
     AGFMWLDKLG LSARMGIEVV MRQVFFGAGN YHLVDENFDP LPDYWLSLLF KKLVGTKVLM
     ASVQGSKRRK LRVYLHCTNT DNPRYKEGDL TLYAINLHNV TKYLRLPYPF SNKQVDKYLL
     RPLGPHGLLS KSVQLNGLTL KMVDDQTLPP LMEKPLRPGS SLGLPAFSYS FFVIRNAKVA
     ACI
//
